Financials data is unavailable for this security.
View more
Year on year Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS 's revenues fell -17.90% from 292.94m to 240.51m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a loss of 20.76m to a larger loss of 79.81m.
Gross margin | 12.64% |
---|---|
Net profit margin | -44.11% |
Operating margin | -31.81% |
Return on assets | -39.93% |
---|---|
Return on equity | -58.76% |
Return on investment | -55.93% |
More ▼
Cash flow in TRYView more
In 2023, Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS increased its cash reserves by 204.11%, or 39.29m. Cash Flow from Financing totalled 118.31m or 49.19% of revenues. In addition the company used 57.33m for operations while cash used for investing totalled 21.69m.
Cash flow per share | -2.98 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 9.56 |
---|---|
Tangible book value per share | 9.34 |
More ▼
Balance sheet in TRYView more
Current ratio | 1.81 |
---|---|
Quick ratio | 1.06 |
Total debt/total equity | 0.3082 |
---|---|
Total debt/total capital | 0.2356 |
More ▼
Growth rates in TRY
Year on year, growth in earnings per share excluding extraordinary items dropped -287.01%.
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | -301.54 |